EMA Refused: Gemesis (becaplermin) — BioMimetic Therapeutics Ltd

View source ↗

Summary

EMA refused Gemesis (becaplermin) by BioMimetic Therapeutics Ltd for guided tissue regeneration and periodontal use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guided Tissue Regeneration Indications
• Periodontal Disease

Drugs mentioned

• Gemesis (becaplermin)

Snippet

Status: Refused. Therapeutic area: Guided Tissue Regeneration, Periodontal. MAH: BioMimetic Therapeutics Ltd. Decision date: 20/11/2009